Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

 
• By Joseph Haas
SC2007_Moving_1094693954_1200.jpg
Bischofberger is jumpstarting R&D by bringing in compounds from his prior company

More from Deals

More from Business